

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Koike et al.

Appl. No.: 10/662,820

Filed: September 16, 2003

For: Quinone-based Therapeutic

Agent for Hepatopathy

Confirmation No.: 1102

Art Unit: 1614

Examiner:

Henley III, Raymond J.

Atty. Docket: 1089.0410001

First Supplemental Information Disclosure Statement

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-SB/08B is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of the document is provided.

The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed May 7, 2004, in connection with the above-captioned application.

The Examiner's attention is drawn to document AJ2 on form PTO/SB/08B. This document was previously submitted as document AF2 in Applicants' Information Disclosure Statement filed May 7, 2004. On that Information Disclosure Statement, Applicants listed the date of on-line publication as July 8, 2002, which is incorrect. The correct date of on-line publication is April 11, 2002, as indicated on the accompanying Form PTO/SB/08B. Applicants request that the examiner line through document AF2 on the original Information Disclosure Statement, and initial document AJ2 on Form PTO/SB/08B.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

Attached is our PTO-2038 Credit Card Payment Form in an amount which includes \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala Attorney for Applicants

Tricket Alwhy

Registration No. 33,851

Date: <u>July 27, 2005</u> 1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

425772_1.DOC

PTO/SB/08B (08-04) Approved for use through 07/31/2006. OMB 0651-0031

1089.0410001/MAC/DJN

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO Complete if Known Application Number 10/662,820 September 16, 2003 FIRST SUPPLEMENTAL Filing Date Koike et al. INFORMATION DISCLOSURE First Named Inventor 1614 Art Unit STATEMENT BY APPLICANT **Examiner Name** Raymond J. Henley, III

Attorney Docket Number

Sheet

of

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author, title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher	T ²
	AJ2	Koike, Y. et al, "Randomized Prospective Study of Prevention from Tumor Invasion into Portal Vein in 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration," available online at: http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31 (April 11, 2002)	
425748 1.DO	<u> </u>		

Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.